# Indel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indel-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.indelrx.com
- Total disclosed funding: $1.4M
- Latest round: Series B (Apr 28, 2011)
- Investors on record: 3

## About

Indel Therapeutics specializes in developing innovative therapies to address unmet medical needs, focusing on advanced treatments for various diseases.Indel Therapeutics, founded in 2008 and headquartered in Vancouver, Canada, is dedicated to the development of groundbreaking therapies. The company has undergone strategic pivots to refine its focus on biotechnology solutions. It has engaged in 2 total deals and most recently raised USD 1.40 mn in a Series B funding round with participation from investors including 5Y Capital, MAD Ventures, and Quantum Pacific Capital.Indel Therapeutics offers a suite of innovative therapies aimed at addressing specific medical challenges. Its core products include cutting-edge treatments designed to improve patient outcomes in the healthcare sector. The company focuses on developing solutions that enhance efficacy and safety, targeting a range of diseases. It primarily serves clients in North America and Europe, where demand for advanced therapeutic options continues to grow.The company's revenue model is based on a combination of product sales and research partnerships, ensuring a steady cash flow while providing clients with access to its comprehensive therapeutic solutions. Engagements are typically structured as multi-year contracts, fostering long-term relationships and stability in revenue streams. The pricing model includes tiered plans to accommodate different healthcare providers, aligning with their operational needs and budgets. Transactions are conducted directly between Indel Therapeutics and healthcare institutions, emphasizing a B2B approach focused on service excellence and patient satisfaction.Indel Therapeutics aims to expand its product portfolio with new therapies set to launch by the end of 2024. The company plans to enter new markets in Asia and South America within the next five years, leveraging recent funding to support research and development, as well as market entry strategies. The funding secured from the recent Series B round will bolster these initiatives, enabling Indel Therapeutics to enhance its capabilities and broaden its market reach.

## Funding rounds

- Series B, Apr 28, 2011, $1.4M — 5Y Capital, Quantum Pacific Capital, MAD Ventures

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Quantum Pacific Capital — Series B
- MAD Ventures — Series B